Avaliação no Mundo Real de um Stent Eluidor de Sirolimus de Hastes Ultrafinas em Pacientes com Infarto do Miocárdio com Supradesnivelamento do Segmento ST Submetidos à Intervenção Coronária Percutânea Primária (Registro INSTEMI)

Araújo, Gustavo Neves de; Machado, Guilherme Pinheiro; Moura, Márcia R. de; Silveira, Anderson Donelli da; Bergoli, Luiz Carlos Corsetti; Fuchs, Felipe Costa; Gonçalves, Sandro Cadaval; Wainstein, Rodrigo Vugman; Lemos, Pedro A.; Quadros, Alexandre Schaan de; Wainstein, Marco Vugman

doi:10.36660/abc.20220594

Cited by 2 publications

(2 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Araujo et al, 9 em seu artigo intitulado: “ Avaliação no Mundo Real de um Stent Eluidor de Sirolimus de Hastes Ultrafinas em Pacientes com Infarto do Miocárdio com Supradesnivelamento do Segmento ST Submetidos à Intervenção Coronária Percutânea Primária (Registro INSTEMI)” analisou dados de um registro multicêntrico de STEMI do mundo real no sul do Brasil e comparou um novo stent ultrafino (75µm) de liga de CrCo com uma eluição de sirolimus de curto prazo (45 dias) de um polímero abluminal biocompatível degradável (9 meses) com uma mistura dos atuais stents workhorses padrão.…”

unclassified

“…In between, newer metallic alloys allowed iterative improvements in strut thickness, flexibility, deliverability, and vessel conformability, making interventionist work much easier now. 8 Araujo et al, 9 in their paper entitled: "Real-World Assessment of an Ultrathin Strut, Sirolimus-Eluting Stent in Patients with ST-Elevation Myocardial Infarction Submitted to Primary Percutaneous Coronary Intervention (INSTEMI Registry)", analyzed data from a real-world STEMI multicenter registry in southern Brazil, and compared a new ultrathin (75µm) CrCo alloy stent with a short term sirolimus elution (45 days) from a biocompatible degradable (9 months) abluminal polymer with a mix of current standard workhorses stents.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Estamos Chegando ao Fim do Caminho Evolutivo para Stents Metálicos Farmacológicos? Quais Stents de 4ª Geração Precisamos?

Almeida¹

2023

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

unclassified

mentioning

confidence: 99%

Estamos Chegando ao Fim do Caminho Evolutivo para Stents Metálicos Farmacológicos? Quais Stents de 4ª Geração Precisamos?

Almeida¹

2023

Arquivos Brasileiros De Cardiologia

View full text Add to dashboard Cite

48-Month Clinical Outcomes and Prognostic Factors in an All-Comers Population with Acute Coronary Syndrome and Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention with a Sirolimus-Eluting Stent

Tyczynski,

Kern,

Buller

et al. 2023

JPM

View full text Add to dashboard Cite

We characterized the performance as well as safety of a second-generation thin-strut sirolimus-eluting stent with a biodegradable polymer, Alex Plus (Balton, Poland), deployed in the acute coronary syndrome (ACS) setting. We enrolled patients who were subjected to percutaneous coronary intervention (PCI) between July 2015 and March 2016 and took into consideration demographics, clinical and laboratory data, and clinical outcomes. We defined the primary endpoint as the 48-month rate of major cardiovascular adverse events (MACE), including cardiac death, myocardial infarction (MI), or target lesion revascularization (TLR). The secondary endpoints were all-cause death, cardiac death, MI, and TLR rates at 12-, 24-, 36-, and 48 months. We enrolled 232 patients in whom 282 stents were implanted, including 88 ACS and 144 chronic coronary syndrome (CCS) patients. The mean age of the ACS population was 67 ± 13 years old, and 32% of it consisted of females. Patients with ACS were characterized by lower rates of arterial hypertension (85.2% vs. 95.8%, p = 0.004), dyslipidemia (67% vs. 81.9%, p = 0.01), prior MI (34.1% vs. 57.6%, p < 0.001), and prior PCI (35.2% vs. 68.8%, p < 0.001). At 48 months, among the ACS patients, the rates of MACE, death, cardiac death, MI, and TLR were 23.9%, 11.4%, 7.9%, 9.1%, and 10.2%, respectively. No stent thrombosis cases were reported. Multivariable Cox regression revealed that the statistically significant MACE predictors were massive calcifications in coronary arteries (HR 9.0, 95% CI 1.75–46.3, p = 0.009), post-dilatation (HR 3.78, 95% CI 1.28–11.2, p = 0.016), prior CABG (HR 6.64, 95% CI 1.62–27.1, p = 0.008), vitamin K antagonist use (HR 5.99, 95% CI 1.29–27.8, p = 0.022), and rivaroxaban use (HR 51.7, 95% CI 4.48–596, p = 0.002). The study findings show that Alex Plus was effective and safe in a contemporary cohort of real-world ACS patients undergoing primary PCI. The outcomes were comparable between the ACS and chronic coronary syndrome patients, with a trend of lower TLR in ACS patients at 4 years.

show abstract

Avaliação no Mundo Real de um Stent Eluidor de Sirolimus de Hastes Ultrafinas em Pacientes com Infarto do Miocárdio com Supradesnivelamento do Segmento ST Submetidos à Intervenção Coronária Percutânea Primária (Registro INSTEMI)

Cited by 2 publications

References 15 publications

Estamos Chegando ao Fim do Caminho Evolutivo para Stents Metálicos Farmacológicos? Quais Stents de 4ª Geração Precisamos?

Estamos Chegando ao Fim do Caminho Evolutivo para Stents Metálicos Farmacológicos? Quais Stents de 4ª Geração Precisamos?

48-Month Clinical Outcomes and Prognostic Factors in an All-Comers Population with Acute Coronary Syndrome and Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention with a Sirolimus-Eluting Stent

Contact Info

Product

Resources

About